Well-positioned to be a long-term supplier of raw material and critical elements to the modern-day infrastructure marketNear-term catalysts expected to...
Interim Phase 1/2 results for cirmtuzumab with ibrutinib in MCL presented at ASH in December 2020 compare favorably to historical...
– Phase 1/2 Trial for Lead Candidate CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3 for the Treatment of Hematologic Malignancies, On...
NEW YORK, March 11, 2021 (GLOBE NEWSWIRE) -- Portman Ridge Finance Corporation (Nasdaq: PTMN) (the “Company” or “Portman Ridge”) announced...
Conference call begins at 4:30 p.m. Eastern time todayNEWTOWN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:...
NORTH HUNTINGDON, Pa.--(BUSINESS WIRE)--Mar 11, 2021--The ExOne Company (Nasdaq: XONE) (“ExOne” or the “Company”), the global leader in industrial sand...
Fourth quarter same-store sales resilient and improved 130 basis points sequentially to (19.7%)Continued to advance new strategic focus on “Traffic-Driven...
Montrouge, France, March 11, 2021DBV Technologies Reports Full-Year 2020 Financial Results and Recent Business Developments DBV Technologies S.A. (Euronext: DBV...
TORONTO, March 11, 2021 /PRNewswire/ - Quarterhill Inc. ("Quarterhill" or the "Company") (TSX: QTRH) (OTCQX: QTRHF), announces its financial results...
- First-in-human dose-escalation study to evaluate ability of ImmTOR™ to mitigate immunogenicity of AAV capsid initiated with initial data expected...
Closed business combination with Panacea, yielding new public listing and strong cash position of approximately $830 millionPatient enrollment ongoing in...
- Continued Focus on Effective Traffic Acquisition and Operational Efficiencies Drive Highest Level of Q4 Gross Profit and Margin Since...
Full Year Net Product Sales of $93.5 Million; Full Year Pro-Forma Revenue of $119.2 Million in Line with GuidancePost Year-end...
Key Business and Financial Highlights22nd Century has a tremendous global commercial opportunity in the more than $800 billion markets across...
− Enrollment Completed in Phase 3 INVIGORATE Trial, with Top-Line Results Expected in the First Half of 2021− Top-Line Results...
Reports positive Phase 1 study results for Voriconazole Inhalation Powder and Tacrolimus Inhalation PowderAwarded subcontract license by U.S. government agency...
Productive Type B Pre-IND Meeting with FDA Provides Clarity for Planned Stroke Study ProgramOn Track to Initiate Phase 2/3 AIS...
Libervant™ (diazepam) Buccal Film New Drug Application (NDA) resubmission expected end of second quarter 2021Epinephrine program and development strategy to...
